Transforming growth factor beta 1 (TGF-β1), a cytokine whose levels are elevated in the airways of patients with asthma, perpetuates airway inflammation and modulates airway structural cell remodeling. However, the role of TGF-β1 in excessive airway narrowing in asthma, or airway hyperresponsiveness (AHR), remains unclear. In this study, we set out to investigate the direct effects of TGF-β1 on human airway smooth muscle (HASM) cell shortening and hyperresponsiveness. The dynamics of AHR and single-cell excitation-contraction (E-C) coupling were measured in human precision-cut lung slices (hPCLS) and in isolated HASM cells using supravital microscopy and magnetic twisting cytometry (MTC), respectively. In hPCLS, overnight treatment with TGF-β1 significantly augmented basal and carbachol-induced bronchoconstriction. In isolated HASM cells, TGF-β1 increased basal and methacholine-induced cytoskeletal stiffness in a dose- and time-dependent manner. TGF-β1-induced single-cell contraction was corroborated by concomitant increases in myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation levels, which were attenuated by siRNA-mediated knockdown of Smad3 and pharmacological inhibition of Rho kinase. Strikingly, these physiologic effects of TGF-β1 occurred through a RhoA-independent mechanism with little effect on HASM cell [Ca2+]i levels. Together, our data suggest that TGF-β1 enhances HASM E-C coupling pathways to induce HASM cell shortening and hyperresponsiveness. These findings reveal a potential link between airway injury-repair responses and bronchial hyperreactivity in asthma, and define TGF-β1 signaling as a potential target to reduce AHR in asthma.